HydraSolve® from Andrew Technologies to be Presented to a Global Audience at Prestigious IMCAS Paris Meeting
January 20, 2015. Tustin, CA. – Andrew Technologies LLC will exhibit for the first time at the upcoming IMCAS Paris meeting, where HydraSolve® will be one of the featured new devices during the Research and Development session on February 1st http://www.imcas.com/en/imcas2015/schedule/session/id/2428. Dr. Christopher Godek, past-President of the New Jersey Plastic Surgery Society and the largest user of HydraSolve®, will present on his experience with HydraSolve® in liposuction and fat transfer patients. During the meeting, Andrew Technologies executives will be available at exhibit booth # WB8 to discuss HydraSolve® with surgeons, potential distributors and Global Key Opinion Leaders. IMCAS is the largest Medical Aesthetic meeting in the world; it has an attendance of over 4,500 from 80 countries.
HydraSolve® is a novel liposuction device based on the same patented Tissue Liquefaction Technology™ that was launched in 2003 by Alcon as the AquaLase® Liquefaction Device for precision cataract surgery. Hydrasolve® combines natural saline solution with low levels of temperature and pressure, to liquefy only targeted fat tissue. Because fat tissue is liquefied, the cutting of fat by forceful thrusts of the cannula is no longer required. The specially designed HydraSolve® cannula is manufactured with aperture edges that have a rounded radius of curvature that do not cut tissue. It is the energized saline stream, inside the cannula, that liquefies targeted fat tissue while not liquefying or cutting blood vessels, nerves or connective tissue. HydraSolve® achieves liquefaction of fat tissue by cell disaggregation, not by emulsification and the lysing of cell membranes. HydraSolve® is the first liposuction device FDA cleared for autologous fat transfer. For more information, please refer to www.hydrasolve.com HydraSolve® is designed to contour the body by removing localized deposits of excess fat and is not intended to treat obesity. Liposuction is a surgical procedure that has risks similar to other minimally invasive cosmetic surgeries.
About Andrew Technologies, LLC
Andrew Technologies, founded in 2007, is a medical technology company committed to improving patients’ lives through body aesthetics and pursuit of surgical applications of Tissue Liquefaction Technology. Andrew Technologies is a venture capital funded company; our primary investors are NJTC Venture Fund www.njtcvc.com, StepStone Group LP www.stepstoneglobal.com and WFD Ventures www.wfdventures.com.